Lung Cancer Treatment Market Size, 2023-2032 Report

Lung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023–2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Industry coverage

1.2&nbsp;&nbsp;&nbsp; Market definitions

1.3&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4&nbsp;&nbsp;&nbsp; Forecast calculations

1.5&nbsp;&nbsp;&nbsp; Data sources

1.6&nbsp;&nbsp;&nbsp; Data validation

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Lung Cancer Treatment industry 360&deg; synopsis, 2018 &ndash; 2032 (USD Million)

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Type trends

2.1.3&nbsp;&nbsp;&nbsp; By Therapy trends

2.1.4&nbsp;&nbsp;&nbsp; End-user trends

2.1.5&nbsp;&nbsp;&nbsp; Regional trends

Chapter 3&nbsp;&nbsp;&nbsp;Lung Cancer Treatment Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of lung cancer across the globe

3.2.1.2&nbsp;&nbsp;&nbsp;The growing trend of smoking tobacco

3.2.1.3&nbsp;&nbsp;&nbsp;Rising levels of air pollution due to rapid industrialization

3.2.1.4&nbsp;&nbsp;&nbsp;Increasing emphasis on early diagnosis of cancers

3.2.1.5&nbsp;&nbsp;&nbsp;Rising technological advancements in lung cancer treatment

3.2.1.6&nbsp;&nbsp;&nbsp;Availability of reimbursement for lung cancer treatment

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;The high cost of lung cancer treatments

3.2.2.2&nbsp;&nbsp;&nbsp;Side effects of drugs and therapies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By type

3.3.2&nbsp;&nbsp;&nbsp; By therapy

3.3.3&nbsp;&nbsp;&nbsp; By end-user

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Clinical trial analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Technology landscape

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Competitive dashboard, 2022

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Company market share analysis, 2022

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.6&nbsp;&nbsp;&nbsp; Strategic outlook matrix, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Lung Cancer Treatment Market Estimates and Forecast, By Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by type

5.2&nbsp;&nbsp;&nbsp; Non-small cell lung cancer

5.3&nbsp;&nbsp;&nbsp; Small cell lung cancer

5.4&nbsp;&nbsp;&nbsp; Carcinoid

Chapter 6&nbsp;&nbsp;&nbsp;Lung Cancer Treatment Market Estimates and Forecast, By Therapy (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by therapy

6.2&nbsp;&nbsp;&nbsp; Radiation therapy

6.3&nbsp;&nbsp;&nbsp; Immunotherapy

6.4&nbsp;&nbsp;&nbsp; Targeted therapy

6.5&nbsp;&nbsp;&nbsp; Chemotherapy

6.6&nbsp;&nbsp;&nbsp; Other therapies

Chapter 7&nbsp;&nbsp;&nbsp;Lung Cancer Treatment Market Estimates and Forecast, By End-user (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by end-user

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Specialty clinics

7.4&nbsp;&nbsp;&nbsp; Homecare

7.5&nbsp;&nbsp;&nbsp; Other end-users

Chapter 8&nbsp;&nbsp;&nbsp;Lung Cancer Treatment Market Size and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Italy

8.3.5&nbsp;&nbsp;&nbsp; Spain

8.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; MEA

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Merck KGaA

9.2&nbsp;&nbsp;&nbsp; ONO PHARMACEUTICAL CO., LTD.

9.3&nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH

9.4&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc.

9.5&nbsp;&nbsp;&nbsp; Pfizer Inc.

9.6&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson Services, Inc.

9.7&nbsp;&nbsp;&nbsp; AstraZeneca

9.8&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited

9.9&nbsp;&nbsp;&nbsp; Church &amp; Dwight Co., Inc.

9.10&nbsp;&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd.Takara Bio Inc.

&nbsp;&nbsp;&nbsp;

Lung Cancer Treatment Market

Inquiry Before Buying